Literature DB >> 10409225

EVE and beyond, retro and prospective insights.

M Rabinovitch1.   

Abstract

Our work has focused on the discovery that an endogenous vascular elastase (EVE) plays a pivotal role in the vascular changes associated with the development and progression of pulmonary hypertension. Recent studies have identified serum factors that stimulate transcription of this enzyme and have elucidated a signal transduction process involving activation of the mitogen-activated protein kinase pathway and nuclear expression of the transcription factor AML1. Proteases release and activate growth factors that are bound to the extracellular matrix and also induce, in a beta(3)-integrin-dependent manner, the transcription of the gene for the matrix glycoprotein tenascin. Tenascin alters smooth muscle cell shape and facilitates the proliferative response to growth factors by clustering and activating growth factor receptors. In addition, breakdown products of elastin, elastin peptides, can upregulate the production of fibronectin, a glycoprotein that is critical to smooth muscle cell migration. The mechanisms regulating enhanced fibronectin production have recently been successfully targeted to prevent the development of intimal lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10409225     DOI: 10.1152/ajplung.1999.277.1.L5

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

Review 1.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 2.  Pulmonary hypertension with left-sided heart disease.

Authors:  Marco Guazzi; Ross Arena
Journal:  Nat Rev Cardiol       Date:  2010-10-05       Impact factor: 32.419

3.  Expression profiles of elastase1 (NvElastaseI) and secretory leukocyte protease inhibitor (NvSLPI) during forelimb regeneration in adult Notophthalmus viridescens suggest a role in epithelial remodeling and delamination.

Authors:  Sandy Gian Vascotto; Shawn Beug; Richard A Liversage; Catherine Tsilfidis
Journal:  Dev Genes Evol       Date:  2006-03-01       Impact factor: 0.900

Review 4.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

Review 5.  Right ventricular afterload and the role of nitric oxide metabolism in left-sided heart failure.

Authors:  Matthias Dupont; W H Wilson Tang
Journal:  J Card Fail       Date:  2013-09-05       Impact factor: 5.712

Review 6.  The structural basis of pulmonary hypertension in chronic lung disease: remodelling, rarefaction or angiogenesis?

Authors:  Natalie Hopkins; Paul McLoughlin
Journal:  J Anat       Date:  2002-10       Impact factor: 2.610

Review 7.  Molecular pathogenesis and current pathology of pulmonary hypertension.

Authors:  Vinicio A de Jesus Perez
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

8.  Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats.

Authors:  Ludek Vajner; Richard Vytásek; Vera Lachmanová; Jirí Uhlík; Václava Konrádová; Jana Novotná; Václav Hampl; Jan Herget
Journal:  Int J Exp Pathol       Date:  2006-10       Impact factor: 1.925

9.  Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation.

Authors:  Katherine Howell; Robert J Preston; Paul McLoughlin
Journal:  J Physiol       Date:  2002-12-13       Impact factor: 5.182

10.  Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells.

Authors:  Xudong Yang; Lu Long; Paul N Reynolds; Nicholas W Morrell
Journal:  Pulm Circ       Date:  2011 Jan-Mar       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.